Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Subscribe To Our Newsletter & Stay Updated